Royalcare Super Speciality Hospitals Unlisted Shares
Royalcare Super Speciality Hospital Limited runs a multi-speciality hospital at Neelambur, Coimbatore in Tamil Nadu. It reported revenue from operations of ₹44,890.37 lakh and profit of ₹2,610.97 lakh for FY26.
Read the full company profile
Key facts
Royalcare Super Speciality Hospitals share details
- Lot size
- 1,000 shares
- Min. investment
- ₹155,000
- Face value
- ₹10
- Implied market cap
- ₹3,176 Cr
- Shares outstanding
- 204,908,478
- Founded
- 2012
- Headquarters
- Coimbatore, Tamil Nadu
- Website
- royalcarehospital.in
- ISIN
- INE02C801010
- CIN
- U85100TZ2012PLC018984
- Lock-in after IPO
- 6 months
Price history
Royalcare Super Speciality Hospitals share price chart
1Y change
+9.15%
High
₹160
Low
₹142
Indicative off-market dealer quotes, not exchange prices. A flat stretch means the quote did not change on those days.
About
About Royalcare Super Speciality Hospitals
Royalcare Super Speciality Hospital Limited was incorporated in 2012 and started hospital operations in 2016. Its flagship is a multi-speciality hospital at Neelambur, Sulur Taluk, Coimbatore, Tamil Nadu. The company says it aims to give international standard hospital care at a reasonable cost. It has no subsidiary, joint venture or associate company.
The business earns money from patient services at the hospital. Its spending shows how a hospital works: consumables and stores, fees paid to consulting doctors, employee costs and stock-in-trade bought for sale. For FY26, the annual report shows revenue from operations of ₹44,890.37 lakh against ₹35,698.50 lakh in FY25, a rise of 25.75%. EBITDA was ₹8,312.52 lakh and profit for the year was ₹2,610.97 lakh, up from ₹947.88 lakh. The FY25 figures were restated after the move to Ind AS.
The company is still building. Capital work-in-progress stood at ₹30,092.31 lakh on 31 March 2026 and property, plant and equipment rose to ₹61,080.13 lakh. This expansion is funded by both new equity and loans. Net worth was ₹45,049.77 lakh, and borrowings were ₹50,609.75 lakh non-current plus ₹4,659.27 lakh current. For the first time since incorporation, the board recommended a dividend of ₹0.20 per share for FY26.
Dr. K. Madeswaran is Chairman cum Managing Director and the main promoter. The annual report lists promoter holdings of 10.89% for him, 1.75% for Dr. K. Chockalingam and 1.06% for Mr. K.P. Alagesan as on 31 March 2026. The company had 204908478 equity shares of ₹10 each on that date. The annual report also records a private placement of shares at ₹62 per share and a proposal to issue shares with differential voting rights to the promoter.
The figures above are standalone, as the company has no subsidiaries. No IPO has been announced on our records. Unlisted shares of a company like this trade off-market between buyers and sellers through dealers, so the price we show, ₹155 per share with a lot of 1000 shares, is only indicative. It implies a market cap of about ₹3176.08 crore on the share count we hold. This is information, not advice.
Strengths
- Revenue from operations grew 25.75% to ₹44,890.37 lakh in FY26 from ₹35,698.50 lakh in FY25.
- Profit for the year rose to ₹2,610.97 lakh in FY26 from ₹947.88 lakh in FY25, with EBITDA at ₹8,312.52 lakh against ₹7,007.81 lakh.
- Net cash from operating activities was ₹8,991.96 lakh in FY26, higher than the ₹2,610.97 lakh profit, because depreciation of ₹3,334.25 lakh is a non-cash charge.
- Finance cost fell to ₹1,617.37 lakh in FY26 from ₹2,224.10 lakh in FY25 even as borrowings grew.
- Net worth increased to ₹45,049.77 lakh on 31 March 2026 from ₹31,627.41 lakh a year earlier, helped by fresh equity and securities premium.
- The board recommended its first dividend since incorporation, ₹0.20 per share, which shows the company is now generating surplus profit.
- The company has no subsidiary, joint venture or associate, so the reported numbers are for a single hospital business.
Risks
- Borrowings are large: ₹50,609.75 lakh non-current and ₹4,659.27 lakh current on 31 March 2026, against net worth of ₹45,049.77 lakh.
- Capital work-in-progress of ₹30,092.31 lakh means a lot of money is tied up in projects that are not yet earning.
- Investing activities used ₹33,003.46 lakh in FY26, funded mostly by new borrowings and equity, so the company depends on continued access to funding.
- Profit before tax was ₹3,360.91 lakh, but earnings per share are only ₹1.33 because the share count has grown to 204908478 shares.
- The business is concentrated in one flagship hospital in Coimbatore, so a local issue can hit most of the revenue.
- Consulting charges to doctors were ₹8,105.77 lakh in FY26, so the hospital relies on retaining its doctors.
- The FY25 profit and balance sheet were restated for the Ind AS transition, which makes year-on-year comparison less clean.
- The company has related party transactions that needed shareholder approval, and the promoter group holds a modest stake of about 10.89% for the managing director.
- Shares are unlisted, so trading is off-market, prices are indicative and exits can take time.
Financials
Royalcare Super Speciality Hospitals financial performance
Revenue, profit and balance-sheet figures by fiscal year.
Revenue & PAT (₹ Cr)
Revenue
PAT
| Metric | FY26Latest | FY25 |
|---|---|---|
| Revenue (₹ Cr) | 449 | 357 |
| EBITDA (₹ Cr) | 83.13 | 70.08 |
| PAT (₹ Cr) | 26.11 | 9.48 |
| EBITDA Margin (%) | 18.52 | 19.63 |
| PAT Margin (%) | 5.82 | 2.66 |
| RoNW (%) | 5.80 | 3.00 |
| EPS (₹) | 1.33 | 0.53 |
| Total Assets (₹ Cr) | 1,075 | 841 |
| Net Worth (₹ Cr) | 451 | 316 |
Swipe the table sideways for earlier years →
Leadership
Management team
Dr. K. Madeswaran
Chairman cum Managing Director
Promoter of the company and holder of 10.89% as on 31 March 2026.
Dr. K. Chockalingam
Director
Promoter director holding 1.75% as on 31 March 2026.
Sri. K.P. Alagesan
Director
Promoter director holding 1.06% as on 31 March 2026.
Dr. Minu Madeswaran
Director
Director who retires by rotation at the next AGM.
CS K.Rangasamy
Company Secretary
Key managerial personnel named in the annual report.
Ready to invest?
CDSL · NSDL
T+1 SETTLEMENT
NO FEE
Buy or sell Royalcare Super Speciality Hospitals unlisted shares
Get a live quote on WhatsApp in under 60 seconds. Current price ₹155. Shares are delivered to your own demat in 24–48 hours, never to a custodian.
Indicative off-market price, not an exchange quote. Read the disclaimer.
FAQs
Royalcare Super Speciality Hospitals unlisted shares: common questions
Important disclaimer
Unlisted shares are not traded on stock exchanges. Prices shown are indicative and based on off-market transactions; they may differ from eventual listing or future market prices. Exit liquidity depends on counter-party availability. SEBI mandates a 6-month lock-in on pre-IPO shares post-listing. Gains held beyond 24 months are taxed at 12.5% LTCG (no indexation). IPO Guru is not a SEBI Registered Investment Advisor. Information here is for general awareness, not personalised investment advice. Please consult your tax advisor before investing.
